CoChat

What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead

Open access
Bassetti, Matteo, Righi, Elda, Montravers, Philippe, Cornely, Oliver A · 2018 · Journal of Antimicrobial Chemotherapy
Cited by 98

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

The treatment of invasive candidiasis has changed greatly in the past decade and must continue to evolve if we are to improve outcomes in this serious infection. A review of recent history may provide insights for the future. The morbidity and mortality of invasive candidiasis remain difficult to measure despite an obvious clinical burden. Current treatment guidelines now recommend echinocandins as first-line empirical treatment, with fluconazole as an acceptable alternative for selected patients, reflecting the efficacy demonstrated by echinocandins and increasing resistance observed with fluconazole. The selection of antifungal therapy now must consider not only resistance but also the shift in predominance from Candida albicans to non-albicans species, notably Candida glabrata. The recent emergence of Candida auris has been met with great interest, although the longer-term implications of this phenomenon remain unclear. The broad goal of treatment continues to be administration of safe, efficacious antifungal therapy as soon as possible. Diagnostic methods beyond traditional blood culture present an opportunity to shorten the time to an accurate diagnosis, and earlier treatment initiation based on prophylactic and empirical or pre-emptive strategies seeks to ensure timely therapeutic intervention. In addition, there are novel agents in the antifungal pipeline. These developments, as well as ongoing studies of dosing, toxicity and resistance development, are important items on the current research agenda and may play a role in future changes to the treatment of invasive candidiasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkx445

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 86

  1. Goldstein, 1972, Problems in the diagnosis and treatment of systemic candidiasis, J Infect Dis, 125, 190, 10.1093/infdis/125.2.190 · DOI · Paper page
  2. Appleyard, 1969, Candida septicaemia, Br Med J, 1, 577, 10.1136/bmj.1.5643.577 · doi:10.1136/bmj.1.5643.577
  3. Shurtleff, 1963, Systemic candida tropicalis infection treated with amphotericin, N Engl J Med, 269, 1112, 10.1056/NEJM196311212692102 · DOI
  4. Cornely, 2015, Hepatosplenic candidiasis, Clin Liver Dis, 6, 10.1002/cld.491 · DOI
  5. Koehler, 2016, Contemporary strategies in the prevention and management of fungal infections, Infect Dis Clin North Am, 30, 265, 10.1016/j.idc.2015.10.003 · DOI
  6. Knitsch, 2015, A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections, Clin Infect Dis, 61, 1671, 10.1093/cid/civ707 · DOI · Paper page
  7. Eliakim-Raz, 2016, Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study, Int J Infect Dis, 52, 49, 10.1016/j.ijid.2016.09.018 · DOI
  8. Bassetti, 2006, Epidemiological trends in nosocomial candidemia in intensive care, BMC Infect Dis, 6, 21., 10.1186/1471-2334-6-21 · DOI · Paper page
  9. Cornely, 2015, Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031), Clin Infect Dis, 61, 324, 10.1093/cid/civ293 · DOI · Paper page
  10. Pappas, 2016, Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis, 62, e1, 10.1093/cid/civ1194 · DOI · Paper page
  11. Bassetti, 2017, Intensive care medicine research agenda on invasive fungal infection in critically ill patients, Intensive Care Med, 10.1007/s00134-017-4731-2 · DOI · Paper page
  12. Rex, 2003, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects, Clin Infect Dis, 36, 1221, 10.1086/374850 · DOI · Paper page
  13. Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, 883, 10.1086/520980 · DOI · Paper page
  14. Blot, 2002, Effects of nosocomial candidemia on outcomes of critically ill patients, Am J Med, 113, 480, 10.1016/S0002-9343(02)01248-2 · DOI · Paper page
  15. Lortholary, 2017, The risk and clinical outcome of candidemia depending on underlying malignancy, Intensive Care Med, 43, 652, 10.1007/s00134-017-4743-y · DOI · Paper page
  16. Koehler, 2014, Our 2014 approach to candidaemia, Mycoses, 57, 581, 10.1111/myc.12207 · DOI
  17. Mann, 2009, Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species, Antimicrob Agents Chemother, 53, 5026, 10.1128/AAC.01031-09 · DOI · Paper page
  18. Seifert, 2007, In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates, Antimicrob Agents Chemother, 51, 1818, 10.1128/AAC.01217-06 · DOI · Paper page
  19. Metwally, 2007, Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001-2006, J Infect, 55, 174, 10.1016/j.jinf.2007.04.003 · DOI
  20. Sharma, 2015, Draft genome sequence of a fluconazole-resistant Candida auris strain from a candidemia patient in India, Genome Announc, 3, 10.1128/genomeA.00722-15 · DOI · Paper page
  21. Ruiz Gaitan, 2017, Nosocomial fungemia by Candida auris: first four reported cases in continental Europe, Rev Iberoam Micol, 34, 23, 10.1016/j.riam.2016.11.002 · DOI · Paper page
  22. Tsay, 2017, Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016-May 2017, MMWR Morb Mortal Wkly Rep, 66, 514, 10.15585/mmwr.mm6619a7 · DOI · Paper page
  23. Clancy, 2017, Emergence of Candida auris: an international call to arms, Clin Infect Dis, 64, 141, 10.1093/cid/ciw696 · DOI · Paper page
  24. Leon, 2012, Value of β-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions, Intensive Care Med, 38, 1315, 10.1007/s00134-012-2616-y · DOI
  25. Held, 2013, Comparison of (1->3)-β-d-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia, J Clin Microbiol, 51, 1158, 10.1128/JCM.02473-12 · DOI · Paper page
  26. Martinez-Jimenez, 2015, Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment, J Antimicrob Chemother, 70, 3107, 10.1093/jac/dkv241 · DOI · Paper page
  27. Bille, 2010, New nonculture-based methods for the diagnosis of invasive candidiasis, Curr Opin Crit Care, 16, 460, 10.1097/MCC.0b013e32833e04df · DOI
  28. Avni, 2011, PCR diagnosis of invasive candidiasis: systematic review and meta-analysis, J Clin Microbiol, 49, 665, 10.1128/JCM.01602-10 · DOI · Paper page
  29. Wallet, 2010, Preliminary clinical study using a multiplex real-time PCR test for the detection of bacterial and fungal DNA directly in blood, Clin Microbiol Infect, 16, 774, 10.1111/j.1469-0691.2009.02940.x · DOI
  30. van Deventer, 1996, Kinetics of anti-mannan antibodies useful in confirming invasive candidiasis in immunocompromised patients, Microbiol Immunol, 40, 125, 10.1111/j.1348-0421.1996.tb03327.x · DOI
  31. Caggiano, 2011, Candida colonization index in patients admitted to an ICU, Int J Mol Sci, 12, 7038, 10.3390/ijms12107038 · DOI
  32. Bassetti, 2013, A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts, Intensive Care Med, 39, 2092, 10.1007/s00134-013-3109-3 · DOI · Paper page
  33. Leon, 2014, What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients, Intensive Care Med, 40, 808, 10.1007/s00134-014-3281-0 · DOI
  34. Liss, 2016, 1,3-β-d-Glucan contamination of common antimicrobials, J Antimicrob Chemother, 71, 913, 10.1093/jac/dkv419 · DOI · Paper page
  35. Liss, 2016, 1,3-ss-d-Glucan concentrations in blood products predict false positive post-transfusion results, Mycoses, 59, 39, 10.1111/myc.12432 · DOI · Paper page
  36. Mikulska, 2016, Lower sensitivity of serum (1,3)-β-d-glucan for the diagnosis of candidaemia due to Candida parapsilosis, Clin Microbiol Infect, 22, 646.e5, 10.1016/j.cmi.2016.05.020 · DOI
  37. Tissot, 2013, β-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis, Am J Respir Crit Care Med, 188, 1100, 10.1164/rccm.201211-2069OC · DOI · Paper page
  38. Martin-Mazuelos, 2015, β-d-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis, Intensive Care Med, 41, 1424, 10.1007/s00134-015-3922-y · DOI
  39. Hanson, 2012, β-d-Glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study, PLoS One, 7, e42282, 10.1371/journal.pone.0042282 · DOI · Paper page
  40. Posteraro, 2011, Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1–>3)-β-d-glucan assay, Candida score, and colonization index, Crit Care, 15, R249, 10.1186/cc10507 · DOI · Paper page
  41. Jaijakul, 2012, 1,3)-β-d-Glucan as a prognostic marker of treatment response in invasive candidiasis, Clin Infect Dis, 55, 521, 10.1093/cid/cis456 · DOI · Paper page
  42. Koo, 2012, Post-diagnostic kinetics of the (1 –> 3)-β-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia, Clin Microbiol Infect, 18, E122, 10.1111/j.1469-0691.2012.03777.x · DOI · Paper page
  43. Poissy, 2014, Presence of Candida cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and Candida colonisation, Crit Care, 18, R135., 10.1186/cc13953 · DOI
  44. Peman, 2011, Clinical factors associated with a Candida albicans germ tube antibody positive test in intensive care unit patients, BMC Infect Dis, 11, 60, 10.1186/1471-2334-11-60 · DOI
  45. Martinez-Jimenez, 2014, Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia, Med Mycol, 52, 270, 10.1093/mmy/myt025 · DOI
  46. Mylonakis, 2015, T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial, Clin Infect Dis, 60, 892, 10.1093/cid/ciu959 · DOI · Paper page
  47. Gorton, 2014, Comparative analysis of Gram's stain, PNA-FISH and Sepsityper with MALDI-TOF MS for the identification of yeast direct from positive blood cultures, Mycoses, 57, 592, 10.1111/myc.12205 · DOI
  48. Wattal, 2017, Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory, Eur J Clin Microbiol Infect Dis, 36, 807, 10.1007/s10096-016-2864-9 · DOI
  49. Huang, 2013, Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia, Clin Infect Dis, 57, 1237, 10.1093/cid/cit498 · DOI · Paper page
  50. Scudeller, 2014, An Italian consensus for invasive candidiasis management (ITALIC), Infection, 42, 263, 10.1007/s15010-013-0558-0 · DOI
  51. Azoulay, 2012, Systemic antifungal therapy in critically ill patients without invasive fungal infection, Crit Care Med, 40, 813, 10.1097/CCM.0b013e318236f297 · DOI · Paper page
  52. Wissing, 2013, Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study, Infect Drug Resist, 6, 15
  53. Epstein, 2018, Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies, J Antimicrob Chemother, 73, i60, 10.1093/jac/dkx450 · DOI
  54. Giannella, 2018, Use of echinocandin prophylaxis in solid organ transplantation, J Antimicrob Chemother, 73, i51, 10.1093/jac/dkx449 · DOI
  55. Presterl, 2009, Invasive fungal infections and (1,3)-β-d-glucan serum concentrations in long-term intensive care patients, Int J Infect Dis, 13, 707, 10.1016/j.ijid.2008.10.013 · DOI · Paper page
  56. Mohr, 2011, Prospective survey of (1–>3)-β-d-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting, J Clin Microbiol, 49, 58, 10.1128/JCM.01240-10 · DOI · Paper page
  57. Bow, 2010, Canadian clinical practice guidelines for invasive candidiasis in adults, Can J Infect Dis Med Microbiol, 21, e122, 10.1155/2010/357076 · DOI · Paper page
  58. Ostrosky-Zeichner, 2014, MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting, Clin Infect Dis, 58, 1219, 10.1093/cid/ciu074 · DOI · Paper page
  59. Leroy, 2016, Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study, Ann Intensive Care, 6, 2, 10.1186/s13613-015-0103-7 · DOI · Paper page
  60. Bailly, 2015, Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients, Am J Respir Crit Care Med, 191, 1139, 10.1164/rccm.201409-1701OC · DOI
  61. Micek, 2014, Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study, Clin Ther, 36, 1226, 10.1016/j.clinthera.2014.06.028 · DOI
  62. Hsu, 2010, A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients, J Antimicrob Chemother, 65, 1765, 10.1093/jac/dkq216 · DOI
  63. Puig-Asensio, 2014, Impact of therapeutic strategies on the prognosis of candidemia in the ICU, Crit Care Med, 42, 1423, 10.1097/CCM.0000000000000221 · DOI · Paper page
  64. Montravers, 2016, Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units, Clin Microbiol Infect, 23, 117 e1, 10.1016/j.cmi.2016.10.001 · DOI
  65. Falagas, 2006, Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies, Crit Care, 10, R48, 10.1186/cc4869 · DOI · Paper page
  66. Reboli, 2011, Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome, BMC Infect Dis, 11, 261, 10.1186/1471-2334-11-261 · DOI · Paper page
  67. Murri, 2016, Initial antifungal strategy does not correlate with mortality in patients with candidemia, Eur J Clin Microbiol Infect Dis, 35, 187, 10.1007/s10096-015-2527-2 · DOI
  68. Ruhnke, 2012, Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients, Clin Microbiol Infect, 18, 680, 10.1111/j.1469-0691.2012.03784.x · DOI · Paper page
  69. Kett, 2011, Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis, Crit Care, 15, R253, 10.1186/cc10514 · DOI · Paper page
  70. Sinnollareddy, 2015, Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study, Crit Care, 19, 33, 10.1186/s13054-015-0758-3 · DOI · Paper page
  71. Pea, 2018, Overview of antifungal dosing in invasive candidiasis, J Antimicrob Chemother, 73, i33, 10.1093/jac/dkx447 · DOI · Paper page
  72. Eschenauer, 2013, Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study, J Antimicrob Chemother, 68, 922, 10.1093/jac/dks482 · DOI · Paper page
  73. Lopez-Cortes, 2016, Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort, Clin Microbiol Infect, 22, 733.e1, 10.1016/j.cmi.2016.05.008 · DOI
  74. Puig-Asensio, 2016, Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections, Antimicrob Agents Chemother, 60, 3291, 10.1128/AAC.00195-16 · DOI
  75. Bassetti, 2014, A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality, Intensive Care Med, 40, 839, 10.1007/s00134-014-3310-z · DOI · Paper page
  76. Bailly, 2015, Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data, Intensive Care Med, 41, 1931, 10.1007/s00134-015-4053-1 · DOI
  77. Seyedmousavi, 2017, Systemic antifungal agents: current status and projected future developments, Methods Mol Biol, 1508, 107, 10.1007/978-1-4939-6515-1_5 · DOI
  78. Katragkou, 2015, Role of echinocandins in fungal biofilm-related disease: vascular catheter-related infections, immunomodulation, and mucosal surfaces, Clin Infect Dis, 61, S622, 10.1093/cid/civ746 · DOI
  79. Ong, 2016, Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin, Antimicrob Agents Chemother, 60, 6872, 10.1128/AAC.00701-16 · DOI · Paper page
  80. Pfaller, 2016, Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates, J Antimicrob Chemother, 71, 2868, 10.1093/jac/dkw214 · DOI · Paper page
  81. Beyda, 2014, FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia, Clin Infect Dis, 59, 819, 10.1093/cid/ciu407 · DOI · Paper page
  82. Ong, 2017, Pharmacokinetics of the novel echinocandin CD101 in multiple animal species, Antimicrob Agents Chemother, 61, 10.1128/AAC.01626-16 · DOI · Paper page
  83. Lepak, 2015, Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model, Antimicrob Agents Chemother, 59, 1265, 10.1128/AAC.04445-14 · DOI · Paper page
  84. Wring, 2017, Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis, Antimicrob Agents Chemother, 61, 10.1128/AAC.02068-16 · DOI · Paper page
  85. Arvanitis, 2014, Molecular and nonmolecular diagnostic methods for invasive fungal infections, Clin Microbiol Rev, 27, 490, 10.1128/CMR.00091-13 · DOI · Paper page
  86. Chang, 2017, New developments and directions in the clinical application of the echinocandins, Arch Toxicol, 91, 1613, 10.1007/s00204-016-1916-3 · DOI

Cited by

See all 98

Metadata

Authors
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A.
Venue
Journal of Antimicrobial Chemotherapy
Published
2018-01-01
Volume
73
Issue
suppl_1
Pages
i14-i25
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2781712060
Cited by
98
References
44
FWCI
8.10
Type
journal article
Language
en
Open access
bronze
Funders
NIH (UM1AI104681)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.